Cogent Biosciences, Inc. (COGT) Stock Forecast
COGT analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 12 analysts
- Price target
- $55.82 average of analyst targets
- Upside to target
- +89.1% from the latest close
- Next earnings
- November 6, 2026 EPS estimate $-0.57
- 52-week range
- $14.13 – $42.84
COGT analyst ratings
12 analystsNumber of analysts at each rating.
COGT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
COGT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.55 | −$0.64 | −$0.43 | −$0.50 | −9.6% | 8 |
| Current fiscal year (2026) | −$2.21 | −$2.54 | −$1.92 | −$2.11 | −4.8% | 9 |
| Next fiscal year (2027) | −$1.18 | −$1.80 | −$0.45 | −$2.21 | +46.9% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
COGT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 11 |
| Current fiscal year (2026) | $6.0M | $0 | $13.8M | 0.0% | 11 |
| Next fiscal year (2027) | $283.7M | $140.2M | $393.0M | +4,637.4% | 11 |
COGT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
COGT revenue: reported and forecast
COGT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.57 | −$0.55 | −$0.55 | −$0.55 | −$0.55 | −3.7% | 5 up · 1 down |
| Current fiscal year (2026) | −$2.26 | −$2.21 | −$2.21 | −$2.21 | −$2.21 | −1.9% | 4 up · 4 down |
| Next fiscal year (2027) | −$0.96 | −$1.13 | −$1.09 | −$1.11 | −$1.18 | +23.1% | 1 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
COGT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; COGT beat in 5 of 12.
What analysts expect from COGT
12 analysts cover Cogent Biosciences; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $55.82, 89.1% above the latest close of $29.52. Analysts expect earnings of −$2.21 per share for 2026, −4.8% from a year earlier. For 2027 the average estimate is −$1.18 per share on revenue of $283.7 million. Cogent Biosciences beat the EPS estimate in 5 of the last 12 quarters.
Related: COGT income statement, COGT key metrics, COGT chart. See the COGT stock overview for the latest quote and news.
COGT forecast FAQ
What is Cogent Biosciences's price target?
The average analyst price target for Cogent Biosciences is $55.82, 89.1% above the latest close of $29.52.
Is Cogent Biosciences a buy, hold or sell?
Of 12 analysts covering Cogent Biosciences, 9 rate it a strong buy, 2 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Cogent Biosciences's EPS forecast?
Analysts forecast −$2.21 per share for 2026 (range −$2.54 to −$1.92); for 2027 the estimate is −$1.18.
What is Cogent Biosciences's revenue forecast?
The average revenue estimate for 2026 is $6.0 million, growth of 0.0%; for 2027 it is $283.7 million.
When does Cogent Biosciences report earnings?
Cogent Biosciences is expected to report results for the quarter ending September 30, 2026 on November 6, 2026; the EPS estimate is $-0.57.
Does Cogent Biosciences usually beat earnings estimates?
Cogent Biosciences reported EPS at or above the analyst estimate in 5 of the last 12 quarters.